Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.

International journal of cancer - 15 May 2012

Messina Rosa Linda, Sanfilippo Mariangela, Vella Veronica, Pandini Giuseppe, Vigneri Paolo, Nicolosi Maria Luisa, Gianì Fiorenza, Vigneri Riccardo, Frasca Francesco

Abstract excerpt

Most undifferentiated thyroid carcinomas express p53 mutants and thereafter, are very resistant to chemotherapy. p53 reactivation and induction of massive apoptosis (Prima-1) is a compound restoring the tumor-suppressor activity of p53 mutants. We tested the effect of Prima-1 in thyroid cancer ce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Apoptosis
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Nerve Tissue Proteins

Share to Thyroid Neoplasms

Share to Tumor Protein p73

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 21647879
DOI: 10.1002/ijc.26228

Genes

BCL2
MDM2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21647879-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.PMID 21647879Read ↗

PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.Semantic proximity Read ↗

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Semantic proximity Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53.Semantic proximity Read ↗

PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.Semantic proximity Read ↗

In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.Semantic proximity Read ↗

Zn(II)-curc targets p53 in thyroid cancer cells.Semantic proximity Read ↗

PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosisSemantic proximity Read ↗

Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.Semantic proximity Read ↗

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read ↗

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.Semantic proximity Read ↗

The p53-homologue p63 may promote thyroid cancer progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.